The Pathobiology of Early Arthritis Cohort (PEAC) is being established through the contribution of a consortium of 5 independent, national centres of excellence. The specific aims of this project are to create an extensively phenotyped cohort of patients with early inflammatory arthritis with linked, detailed pathobiological data.
This study will generate a unique bio-medical resource with high-density data including gene expression profiling, proteomics, metabonomics, genotyping, serum and synovial fluid cyotokine & chemokine analysis, biological tissue characterisation, state-of-the-art ultrasound imaging, and detailed clinical phenotyping. This resource will therefore enable assessment of the role of a spectrum of molecular and cellular pathways that may be involved in disease susceptibility, heterogeneity and treatment response.
In this context, this resource will represent a valuable tool in identification and characterization of early biomarkers of disease development and progression and, may elucidate key pathways involved in perpetuation or resolution of inflammation. This in turn will facilitate precise and predictive biomarker lead therapeutic intervention and, provide a capacity to conduct early proof of concept studies as well as a capacity to engage therapeutic strategies with the long-term aim of induction of remission.
The PEAC cohort therefore, will constitute an ideal platform for innovative clinical trials of novel therapeutics. Additionally, this cohort will enable the development of better prognostic algorithms that will form a rational platform on which to test and, deliver innovative therapeutic modalities, tailored to the needs of the individual.
The PEAC cohort will hence have a major impact on disease management as well as research scope and strategy and thus, be of significant interest to academic and clinical research, the pharmaceutical industry and government bodies. A research mode is shown below.
Aims and objectives of PEAC